Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society.

Giovanni Savettieri, Mancardi, Cottone, Bergamaschi, Sotgiu, Centonze, Gallo, Bellantonio, Vincenzo Brescia Brescia Morra, Millefiorini, Lugaresi, Trojano, Ghezzi, Capra, Pozzilli, Antonio Bertolotto, Marrosu, Tola, Montanari, Luigi M.E. GrimaldiDurelli, Provinciali, Gioacchino Tedeschi, Maria Pia Amato, Domenico Caputo, Comi

    Research output: Contribution to journalArticlepeer-review

    13 Citations (Scopus)

    Abstract

    Three years after the introduction of natalizumab(NA) therapy for the second line treatment of relapsingremitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficaciuos in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.
    Original languageEnglish
    Pages (from-to)351-358
    Number of pages8
    JournalNeurological Sciences
    Volume32
    Publication statusPublished - 2011

    All Science Journal Classification (ASJC) codes

    • Dermatology
    • Clinical Neurology
    • Psychiatry and Mental health

    Fingerprint Dive into the research topics of 'Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society.'. Together they form a unique fingerprint.

    Cite this